Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA requests additional information from VIVUS regarding Qnexa NDA

Nov. 2, 2010

Febuxostat launched for hyperuricemia in Canada

Oct. 29, 2010

Nippon Chemiphar claims new PPAR-delta receptor agonists

Oct. 29, 2010

Validation of DM-199 shown by significantly increasing insulin sensitivity

Oct. 29, 2010

Eisai discontinues development of antiobesity drug KES-524

Oct. 29, 2010

Nascobal to be commercialized outside U.S. for vitamin B12 deficiency

Oct. 28, 2010

PTC Therapeutics begins phase II ataluren trial in nmMMA

Oct. 28, 2010

BMPR-1A inhibition by RAP-661 increases bone mass and strength in mice

Oct. 28, 2010

ViaDerm delivery system meets endpoints in phase I osteoporosis trial

Oct. 27, 2010

Roche patents new glucocorticoid receptor antagonists

Oct. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...